New Doximity Study Shows Modest Physician Pay Growth Amid Deeper Workforce Strain, Reimbursement Pressures
'This year's study reflects a profession that's been under strain for years,' said Amit Phull, MD, chief clinical experience officer at Doximity. 'Pediatricians and pediatric subspecialists, in particular, are facing acute challenges. They're caring for some of the most vulnerable and complex patients in medicine, yet persistently lower pay and reimbursement threaten both workforce stability and patient access to care.'
With over 80% of U.S. physicians as members, Doximity maintains one of the largest physician compensation data sets in the U.S. This year's compensation data draw from approximately 230,000 survey responses over six years, including more than 37,000 U.S. physician responses in 2024. The study also incorporates thousands of physician responses to additional surveys and polls fielded throughout 2024 and 2025.
Report Highlights
Gender and Specialty Pay Gaps
In 2024, average physician compensation rose 5.7% for men and 1.7% for women. The gender pay gap returned to 26%, up from 23% in 2023 and matching the gap reported in 2022. Women physicians earned less than men in all specialties studied, even after controlling for specialty, location, and years of experience.
Pediatric subspecialists earned significantly less than their adult-medicine counterparts despite comparable training and clinical demands. The largest pay gaps were seen in hematology and oncology, with a 93% pay gap.
Primary care physicians also earned considerably less than their specialist colleagues. In 2024, surgical specialists earned 87% more than primary care physicians, down from 100% in 2022.
Pediatric Care Under Pressure
In a June 2025 survey of over 1,200 U.S. pediatricians and pediatric subspecialists:
Over 90% reported they are concerned that current reimbursement levels are interfering with early intervention and prevention efforts in pediatric care.
Half reported that current reimbursement limits their ability to provide care for their pediatric patients; another 37% are worried it could limit care in the future.
The majority (87%) do not believe reimbursement levels adequately align with the needs and complexity of today's pediatric population.
Systemwide Strain and Uncertainty
In a June 2025 survey of over 1,100 U.S. physicians across multiple specialties:
Nearly 60% reported they are concerned that reimbursement pressures will affect their ability to care for Medicare or Medicaid patients in the next 12 months.
17% said they or their organization have already reduced the number of Medicare or Medicaid patients they see in the past 12 months; another 13% said they are likely to.
81% agreed that reimbursement policy has played a significant role in the decline of independent practices in their field. Just 7% of physicians disagreed.
In separate Doximity polls of over 2,000 U.S. physicians (May and June 2025):
85% reported being overworked, with more than two-thirds looking for an employment change or considering early retirement.
77% reported they would be willing to accept, or have already accepted, lower compensation for greater autonomy or work-life balance, up from 75% in 2024 and 71% in 2023.
Read Doximity's 2025 Physician Compensation Report.
About Doximity
Founded in 2010, Doximity is the leading digital platform for U.S. medical professionals. The company's network members include more than 80% of U.S. physicians across all specialties and practice areas. Doximity provides its verified clinical membership with digital tools built for medicine, enabling them to collaborate with colleagues, stay up to date with the latest medical news and research, manage their careers and on-call schedules, streamline documentation and administrative paperwork, and conduct virtual patient visits. Doximity's mission is to help doctors be more productive so they can provide better care for their patients.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
an hour ago
- Business Wire
Median Technologies Has Completed a Capital Increase of € 23.9 Million
SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)--Regulatory News: Not to be published, distributed or disseminated, directly or indirectly, in the United States of America, Australia, Canada, South Africa and Japan Median Technologies (FR0011049824, ALMDT, PEA-PME scheme eligible, 'Median' or the 'Company'), manufacturer of eyonis®, a suite of artificial intelligence (AI) powered Software as a Medical Device (SaMD) for early cancer diagnosis, and a leading provider of AI-based image analyses and central imaging services for oncology drug developers, today announces the success of its capital increase targeting institutional and retail investors through a priority subscription period, a public offering, and a private placement with qualified investors (together, the 'Offering'). The Offering was exclusively open to investors, whether retail or institutional, subscribing for a minimum amount of €100,000 per investor. As a result, subscription requests for a total amount below €100,000 per investor were not allocated. The Offering, launched on July 23, 2025, amounted to a total gross proceed of 23.9 million euros, including the issuance premium. The Company exercised the extension clause granted by the Board of Directors as part of the transaction for an amount of 1.9 million Euros. "I would like to thank all our investors—both institutional and individual—for their support and trust during this capital increase. We are particularly proud to have expanded and strengthened our shareholder base with the participation of renowned Swedish, US, French, German and UK investors (Lungstrom Family Office, Lion Point Life Science Partners, Celestial Successor Fund, Matignon Finance, Invus, Herald Investment Trust, et Tragara Holdings). We also welcome the continued commitment of representatives of the Brag family and friends, who have renewed their trust in the future of the Company. 'This equity financing adds to the up to €37.5 million EIB financing line signed in July 2025 and allows us to meet the contractual conditions to draw down the first €19 million tranche. The Company's cash runway is now extended through the fourth quarter of 2026, and potentially way beyond with the full exercise of the warrants, which can generate additional equity of €51.7 million', said Fredrik Brag, CEO and Founder of Median Technologies. 'This transaction provides us with the solid financial resources needed for the commercial launch of our Software as a Medical Device eyonis® LCS in the United States, while also strengthening our position to finalize negotiations with commercial partners for the distribution of our eyonis® LCS product. Furthermore, the funds raised will also enable us to continue and accelerate our technological and clinical development efforts for the next medical imaging software devices in our eyonis® suite—namely, eyonis® IPN for the incidental detection of lung cancer, and eyonis® HCC for the early diagnosis of primary liver cancer', Brag added. Main terms of the Offering The Offering, carried out with the cancellation of shareholders' preferential subscription rights and including a five-trading-day subscription period (on both irreducible and reducible bases), amounted to total gross proceeds of 23.9 million euros, including the issuance premium. In accordance with the Regulation (EU) 2017/1129, the Offering was addressed to investors, whether retail or institutional, who will subscribe to it for a total consideration of at least €100,000 per investor. In total, the Offering resulted in the issuance of 14,424,541 new ordinary shares of the Company (the 'New Shares'), each accompanied by a warrant (the 'Warrants' and, together with the New Shares to which they are attached, the 'ABSA'). The new ABSA were issued at a price of €1.66 per ABSA, including the issuance premium, representing approximately 72.3% of the Company's existing share capital on a non-diluted basis. This price reflects a nominal discount of 17.9% compared to the volume-weighted average price (VWAP) of the Company's shares over the twenty trading days preceding and through the date of July 18, 2025. The Offering was allocated as follows: On an irreducible and reducible basis during the priority subscription period to existing shareholders: 9,201,890 new ABSA, representing 64% of the capital increase, As part of the public offering in France: 241,224 new ABSA, representing 2% of the capital increase, As part of the Global placement targeting qualified investors (the 'Global Placement'), which included (a) a private placement to a limited number of accredited investors (as defined in Rule 501(a) of the U.S. Securities Act of 1933 (the 'Securities Act')) and/or qualified institutional buyers (as defined in Rule 144A of the Securities Act), and (b) an international offering outside the United States in 'offshore transactions' pursuant to Regulation S of the Securities Act ('Regulation S'), (A) within the European Union (including France), to qualified investors as defined in Article 2(e) of Regulation (EU) 2017/1129 of the European Parliament and of the Council of June 14, 2017, as amended, and (B) outside the European Union (excluding South Africa, Japan, Australia, and Canada) in accordance with applicable laws in each relevant jurisdiction: 4,981,427 new ABSA, representing 35% of the capital increase. Settlement and delivery of the ABSA and their admission to trading on the Euronext Growth Paris market is expected to take place on August 5, 2025. The New Shares will be of the same class and fully fungible with the Company's existing ordinary shares, will carry all rights attached to existing shares, and will be admitted to trading on Euronext Growth Paris under the same ISIN code: FR0011049824 - ALMDT. Two warrants attached to the new shares entitle the holder thereof to subscribe for three new ordinary shares of the Company at a total exercise price of €7.17, i.e., an exercise price of €2.39 per new ordinary share. The theoretical value of each warrant is €0.90 per new ordinary share, based on the Black-Scholes model and assuming a volatility of 76%. The warrants will be detached from the new shares immediately upon issuance and will be admitted to trading on Euronext Growth under ISIN code FR0014011D04. The full exercise of the 14,424,541 warrants subscribed as part of the Offering would represent additional gross proceeds of 51.7 million euros. The warrants will expire 30 months after their issuance date, i.e., on 5 February 2028. The Offering did not and will not require the preparation of a prospectus subject to approval by the French Financial Markets Authority (Autorité des Marchés Financiers), in accordance with Article 1.4.d) of Regulation (EU) 2017/1129 of the European Parliament and of the Council dated June 14, 2017, as amended. Intended use of the transaction's net proceeds Approximatively one-third of the net proceeds will be used to support eyonis® Lung Cancer Screening (LCS) progress towards major milestones consisting of commercial launch and sales development in the U.S, Approximatively one-third of the net proceeds will be used to accelerate the expansion of Median's proprietary suite of Software as a Medical Device, eyonis®, for image-based early cancer diagnosis, notably the scientific and clinical development of Software as a Medical Devices for incidental findings of pulmonary nodules (eyonis® IPN) and liver cancer early diagnosis (eyonis® HCC), and Approximately one-third of the net proceeds will be used to finance the Company's general corporate needs and to support its cash position through the fourth quarter of 2026. Furthermore, successful settlement and delivery of the Offering is expected to allow the Company to fulfill its contractual obligations with the European Investment Bank (EIB), enabling the drawing down of the €19 million first tranche of the new financing facility without delay. The signature of the new EIB financing facility of a total amount of €37.5 million had been announced on July 11, 2025. Impact of the Offering on the Company's shareholding structure Financial intermediary TP ICAP Midcap acted as global coordinator and bookrunner for the Offering. Risk factors The principal risk factors related to the Offering are spelled out below: Shareholders who did not subscribe to the Offering will have their percentage interest in the Company's equity diluted as a result of the issuance of the New Shares, and may experience further dilution upon the potential exercise of the Warrants as well as, more generally, through any future capital increases that may be required to support the Company's financing needs. The market price of the Company's shares could fluctuate and fall below the subscription price of the ABSAs and/or not reach a sufficient level to make the exercise of the BSAs attractive. The volatility and the liquidity of the Company's shares could fluctuate significantly. Those other risk factors relating to the Company and its activities contained in Note 6, Section ' P. Specific Risk Factors' to the Company's Annual Financial Report, available on the Company's website in the 'Investors' section. Forward-looking statements This press release contains forward-looking statements. These statements are not historical facts. They include projections and estimates, as well as the assumptions on which these are based, statements concerning projects, objectives, intentions, and expectations with respect to future financial results, events, operations, services, product development and potential, or future performance. These forward-looking statements can often be identified by the words "expects," "anticipates," "believes," "intends," "estimates" or "plans" and any other similar expressions. Although Median's management believes that these forward-looking statements are reasonable, investors are cautioned that forward-looking statements are subject to numerous risks and uncertainties, many of which are difficult to predict and generally beyond the control of Median Technologies, that could cause actual results and events to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. All forward-looking statements in this press release are based on information available to Median Technologies as of the date of the press release. Median Technologies does not undertake to update any forward-looking information or statements, subject to applicable regulations, in particular Articles 223-1 et seq. of the General Regulation of the French Autorité des Marchés Financiers. About Median Technologies: Pioneering innovative software as a medical device and imaging services, Median Technologies harnesses cutting-edge AI to enhance the accuracy of early cancer diagnoses and treatments. Median's offerings include iCRO, which provides medical image analysis and management in oncology trials, and eyonis®, an AI/ML tech-based suite of software as a medical device (SaMD). Median empowers biopharmaceutical entities and clinicians to advance patient care and expedite the development of novel therapies. The French-based company, with a presence in the U.S. and China, trades on the Euronext Growth market (ISIN: FR0011049824, ticker: ALMDT). Median is also eligible for the French SME equity savings plan scheme (PEA-PME). For more information, visit Disclaimer This announcement is an advertisement and not a prospectus within the meaning of Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017, as amended (the ' Prospectus Regulation '). The offer of Median Technologies shares described above does not constitute a public offering requiring the publication of a prospectus to be approved by the Autorité des Marchés Financiers or a document including the information provided for in Annex IX of the Prospectus Regulation. Median Technologies draws the public's attention to Note 6, section 'P. Specific Risk Factors' of its 2024 Annual Financial Report, published on April 29, 2025, and available free of charge on its website at This press release does not constitute and shall not be construed as an offer to the public, a solicitation, or a sale in any jurisdiction in which such an offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction. The offer of Median Technologies shares described above has been made in the context of (i) a share capital increase without preferential subscription rights through a public offering and with a priority subscription right, on a irreducible and reducible basis, to the benefit of shareholders in France, and (ii) a global placement for institutional investors in France and outside of France, but excluding, in particular, United States, Canada, Japan, South Africa and Australia. The Offering was addressed exclusively to investors subscribing for at least €100,000 per investor. With respect to Member States of the European Economic Area, no action has been taken or will be taken to permit a public offering of the securities referred to in this press release requiring the publication of a prospectus or a document including the information provided for in Annex IX of the Prospectus Regulation in any such Member State. Therefore, such securities may not be and shall not be offered in any Member State other than in accordance with the exemptions of Article 1(4) of the Prospectus Regulation, otherwise, in cases not requiring the publication of a prospectus under Article 3 of the Prospectus Regulation or an information document pursuant to Articles 1(4) and 1(5) of the Prospectus Regulation and/or the applicable regulations in such Member State This press release and the information it contains are being distributed to and are only intended for persons who are (x) outside the United Kingdom or (y) in the United Kingdom who are qualified investors (as defined in the Prospectus Regulation as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018) and are (i) investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the ' Order '), (ii) high net worth entities and other such persons falling within Article 49(2)(a) to (d) of the Order (' high net worth companies ', 'unincorporated associations', etc.) or (iii) other persons to whom an invitation or inducement to participate in investment activity (within the meaning of Section 21 of the Financial Services and Market Act 2000) may otherwise lawfully be communicated or caused to be communicated (all such persons in (y)(i), (y)(ii) and (y)(iii) together being referred to as ' Relevant Persons '). Any invitation, offer or agreement to subscribe, purchase or otherwise acquire securities to which this press release relates will only be engaged with Relevant Persons. Any person who is not a Relevant Person should not act or rely on this press release or any of its contents. This press release may not be distributed, directly or indirectly, in or into the United States. This press release and the information contained therein does not constitute an offer of securities for sale, nor the solicitation of an offer to purchase, Median Technologies' securities in the United States or any other jurisdiction where restrictions may apply. Securities may not be offered or sold in the United States absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended (the 'U.S. Securities Act'). The securities of Median Technologies have not been and will not be registered under the Securities Act, and Median Technologies does not intend to conduct a public offering in the United States. The distribution of this press release may be subject to legal or regulatory restrictions in certain jurisdictions. Any person who comes into possession of this press release must inform him or herself of and comply with any such restrictions. Any decision to subscribe for or purchase the shares or other securities of Median Technologies must be made solely based on information publicly available about Median Technologies. Such information is not the responsibility of TP ICAP Midcap and has not been independently verified by TP ICAP Midcap.
Yahoo
2 hours ago
- Yahoo
Michigan moms could soon have easier access to group prenatal care that's changing lives
Picture this: instead of rushing through a prenatal appointment alone, you join a circle of eight or so expectant parents due around the same time. Over 90 relaxed minutes, you learn about stress management and breastfeeding, get individual check-ins from your provider, and build real relationships with other parents-to-be who actually get what you're going through. This is the heart of CenteringPregnancy, and if new legislation moves forward, moms across Michigan could soon have better access to this kind of support. On July 1, the Michigan Senate passed Senate Bills 414 and 415, which would require both private insurers and Medicaid to cover these group-based prenatal care programs. Related: New CDC data shows that more pregnant women are unable to access prenatal care Why it matters: the science of community prenatal care The idea is simple: you get your prenatal care in a group setting, alongside other pregnant people. But the impact goes way beyond the check-up. CenteringPregnancy helps normalize the experience of motherhood, offering emotional support and measurable health benefits. Studies have shown major benefits: A 33–47% drop in preterm births in randomized trials, with even stronger effects for Black mothers—a meaningful step toward addressing racial disparities in birth outcomes. A 40% reduction in postpartum depression symptoms at six months, according to a meta-analysis. For families already facing barriers to care, these improvements are life-changing. More than medical care: building a village Beyond the metrics, the emotional benefit of group prenatal care is hard to overstate. CenteringPregnancy creates space for parents to share fears, questions, and excitement with people on the same journey. It turns what can feel like a medical transaction into a shared rite of passage. For many moms, it means leaving appointments feeling empowered, informed, and less alone. It can also help detect mental health challenges earlier, improve breastfeeding success, and reduce feelings of isolation that so often accompany pregnancy and postpartum life. What the Michigan bills would change The two bills passed by the Senate aim to make this model a standard part of care—not just a nice-to-have pilot. Senate Bill 414 would require private insurers who already cover prenatal care to include group prenatal care in their plans. Senate Bill 415 would permanently secure Medicaid coverage for CenteringPregnancy in Michigan. (Medicaid already reimburses for it—but this law would ensure it stays that way.) By putting these requirements into law, the state would ensure consistent, widespread access, even if budgets or administrations change. Related: New York is officially the first state to mandate PTO for prenatal care A model the rest of the country should be watching Supporters of the legislation see Michigan as a potential national example. They argue that expanding CenteringPregnancy access is one of the simplest ways to improve maternal and infant health while also saving money on avoidable NICU stays and complications. For families, it represents a shift away from fragmented, rushed care toward a model that's relational, supportive, and proven to work. As a mom of five kids who was underwhelmed with the traditional prenatal care model, I'm excited about a healthcare system that doesn't just provide clinical insights, but also human connection. What's more intimate, life-transforming, and support-group worthy than bringing a new baby into the world? Sources: CenteringPregnancy: A model of group prenatal care. 2023. Centering Healthcare Institute. CenteringPregnancy: A model of group prenatal care. Group prenatal care reduces risk of preterm birth. October 2016. YaleNews. Group prenatal care reduces risk of preterm birth. Group prenatal care: A systematic review and meta-analysis of randomized controlled trials. November 2019. Obstetrics & Gynecology. Group prenatal care: A systematic review and meta-analysis of randomized controlled trials. SB 414 and SB 415. July 2024. Michigan Legislature. SB 414 and SB 415.
Fox News
3 hours ago
- Fox News
Dr. Oz details the new digital health ecosystem
Dr. Mehmet Oz, administrator for the Centers for Medicare & Medicaid Services, discusses the Trump administration's efforts to eradicate Medicare and Medicaid fraud and build a digital health ecosystem on 'Hannity.'
